Figure 3.
ATTM inhibits cuproptosis in macrophages, impedes cardiomyocyte apoptosis and relieves HF after AMI in mice. (A-C) Cu2+ level, ATP content, and SDH activity in mouse macrophages determined by kits, n = 12; (D) Levels of cuproptosis-related proteins FDX1 and DLAT in mouse macrophages measured by western blot, n = 12; (E) Mitochondrial damage in cells assessed by TEM; Levels of HMGB1 (F), IL-1β (G), and TNF-α (H) in mouse serum measured by ELISA, n = 12; LVEF (I) and LVEDP (J) detected by echocardiography, n = 12; K, The NT-proBNP level in mouse serum measured by ELISA, n = 12; L, Representative images of TTC-stained heart sections and quantification of myocardial infarction, n = 6; M, Cardiomyocyte apoptosis assessed by TUNEL staining, n = 6. Data were described as mean ± standard deviation, with multi-group comparisons conducted by one-way ANOVA, followed by Tukey’s post hoc tests. *p < 0.05, **p < 0.01, ***p < 0.001.
